ABSTRACT
Globally, men have higher tuberculosis (TB) burden but the mechanisms underlying this sex disparity are not fully understood. Recent surveys of social mixing patterns have established moderate preferential within-sex mixing in many settings. This assortative mixing could amplify differences from other causes. We explored the impact of assortative mixing and factors differentially affecting disease progression and detection using a sex-stratified deterministic TB transmission model. We explored the influence of assortativity at disease-free and endemic equilibria, finding stronger effects during invasion and on increasing male:female prevalence (M:F) ratios than overall prevalence. Variance-based sensitivity analysis of endemic equilibria identified differential progression as the most important driver of M:F ratio uncertainty. We fitted our model to prevalence and notification data in examplar settings within a fully Bayesian framework. For our high M:F setting, random mixing reduced equilibrium M:F ratios by 12%(95%CrI 0 - 30%). Equalizing male case detection there led to a 20% (95%CrI 11 - 31%) reduction in M:F ratio over 10 years - insufficient to eliminate sex disparities. However, this potentially achievable improvement was associated with a meaningful 8%(95%CrI 4 - 14%) reduction in total TB prevalence over this time frame.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
DSA is supported under the EDCTP2 programme supported by the European Union (grant number RIA2016S-1632-TREATS). PJD is supported by a Career Development Award from the UK MRC (MR/P022081/1). This UK funded award is part of the EDCTP2 programme supported by the European Union.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a mathematical modelling of tuberculosis transmission. Therefore, the study did not collect data from human subjects. We used publicly available prevalence and notifications data (from published reports), and thus IRB approval was not sought
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Link to the model codes is presented in the manuscript